Hyperactive transforming growth factor-beta (TGF-β) signaling could be a signature event in mesenchymal GBM, leading to dysregulation of downstream targets and contributing to malignant transformation [10, 11]. The gene discussed is TGFB1; the disease is glioblastoma.